SPL 0.00% 9.7¢ starpharma holdings limited

Ann: Starpharma to commence DEP cabazitaxel phase 1/2 trial, page-12

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,274 Posts.
    lightbulb Created with Sketch. 451
    I wonder if Sanofi might lob an offer at SPL for this (if they aren't already involved)? If they are going to lose their Jevtana market share to SPL, given the spending spree Sanofi is on at the moment, it could get interesting.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.